Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage.

We hypothesized that the immunological reaction against extravasated blood might play a role in the development of vasospasm after subarachnoid hemorrhage. Under the hypothesis, we had reported significant therapeutic efficacy of cyclosporin A on vasospasm in canine models. We here investigated the efficacy of a new, potent immunosuppressant, FK-506, on vasospasm in animal models. Dogs were randomly classified into sham operated, subarachnoid hemorrhage treated-1 group, (FK-506, 0.3 mg/kg-d, intramuscular injection), and treated-2 group (FK-506, 0.15 mg/kg-d, intramuscular injection). Levels of the third factor of complement (C3) and the activity of serum complement inducing 50% hemolysis of sheep erythrocytes (CH50) in serum were also determined. In the treated groups, the levels of FK-506 in serum were monitored. As for C3 and CH50, there were no statistically significant differences among the groups and there were no changes between Day 1 and Day 7 in any group. Angiographical diameters of a basilar artery on Days 1 and 7 were measured with a computed image analyzer, and the extent of vasospasm was compared among the groups. Statistically significant differences between the sham-operated group and the other three groups were noted. However, under sufficient levels of FK-506 in serum, the extent of vasospasm in either treated group was the same as that in the subarachnoid hemorrhage group. These results indicate a significant discrepancy in the therapeutic mechanism for vasospasm between cyclosporin A and FK-506. They have common aspects in the immunosuppressive mechanism. However, in T-cell suppression, the different mechanism in situ between the two drugs is also postulated.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  S. Schreiber,et al.  Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Nio,et al.  Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. , 1992, Transplantation Proceedings.

[3]  W. Li,et al.  Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. , 1992, Journal of immunology.

[4]  Kazutomo Inoue,et al.  A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs , 1992, Biotherapy.

[5]  S. Hasegawa,et al.  Dose response to FK 506 in canine lung transplantation. , 1991, Transplantation Proceedings.

[6]  I. Yada,et al.  Immunosuppressive effects of FK 506 in rat lung transplantation. , 1991, Transplantation proceedings.

[7]  S. Hasegawa,et al.  FK 506 and cyclosporine: effects and side effects in canine lung transplantation. , 1991, Transplantation Proceedings.

[8]  Y. Nio,et al.  Effects of FK 506 on in vivo immunity in comparison to cyclosporine. , 1991, Transplantation Proceedings.

[9]  A. Górski,et al.  Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. , 1991, Transplantation.

[10]  J. Peterson,et al.  The role of inflammation in experimental cerebral vasospasm. , 1990, Journal of neurosurgery.

[11]  J. Peterson,et al.  Evidence of the role of hemolysis in experimental cerebral vasospasm. , 1990, Journal of neurosurgery.

[12]  J. Peterson,et al.  Cyclosporine A reduces cerebral vasospasm after subarachnoid hemorrhage in dogs. , 1990, Stroke.

[13]  J. Peterson,et al.  Immunological reaction against the aging human subarachnoid erythrocyte. A model for the onset of cerebral vasospasm after subarachnoid hemorrhage. , 1989, Journal of neurosurgery.

[14]  N. Isegawa,et al.  Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. , 1989, Transplantation.

[15]  F. Marks,et al.  The immunosuppressant FK-506, like cyclosporins and didemnin B, inhibits calmodulin-dependent phosphorylation of the elongation factor 2 in vitro and biological effects of the phorbol ester TPA on mouse skin in vivo. , 1989, Immunobiology.

[16]  T. Kobayashi,et al.  Blood levels of FK506 after intramuscular and intravenous administration in dogs. , 1989, Transplantation Proceedings.

[17]  A. Thomson.  FK-506--how much potential? , 1989, Immunology today.

[18]  K. Isono,et al.  STUDIES OF THE EFFECTS OF FK506 ON RENAL ALLOGRAFTING IN THE BEAGLE DOG , 1987, Transplantation.

[19]  Mangan Kf.  Immunologic control of hemopoiesis: implications for quality of the graft after allogeneic bone marrow transplantation. , 1987 .

[20]  M. Okuhara,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987, The Journal of antibiotics.

[21]  K. Isono,et al.  Prolongation of canine renal allograft survival by treatment with FK-506. , 1987, Transplantation proceedings.

[22]  B. Kristensen,et al.  Immune complexes and complement activation following rupture of intracranial saccular aneurysms. , 1987, Journal of neurosurgery.

[23]  T. Starzl,et al.  Biopharmaceutical aspects of FK-506. , 1987, Transplantation proceedings.

[24]  T. Sundt,et al.  Response of chronic experimental cerebral vasospasm to methylprednisolone and dexamethasone. , 1984, Journal of neurosurgery.

[25]  T. Sundt,et al.  Prevention of chronic experimental cerebral vasospasm with ibuprofen and high-dose methylprednisolone. , 1983, Journal of neurosurgery.

[26]  P. Black,et al.  Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a "two-hemorrhage" canine model. , 1983, Journal of neurosurgery.